NEW YORK (GenomeWeb News) – Alnylam today said that it has joined GlaxoSmithKline in contributing more than 1,500 issued or pending patents covering RNA interference technology to a patent pool for neglected tropical diseases.

The patent pool was established by London-based GlaxoSmithKline earlier this year to aid in the discovery and development of new medicines for treating 16 neglected tropical diseases, as defined by the US Food and Drug Administration, in the world's least developed countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.